pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›JOURNAVX
drug · small molecule
save

JOURNAVX

updated 6mo ago
/ soo-ZE-tri-jeen /
by $VERX Vertex, Inc.🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 4
  • drugsuzetrigine9 co-mentions · 3 sources
  • tagApproval8 co-mentions · 2 sources
  • tagSmall Molecule4 co-mentions · 2 sources
  • tagPain1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 2 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying JOURNAVX

  • phase3Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)active not recruitingn=455
  • phase4A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeriescompletedn=100
  • phase4Suzetrigine for Non-Mastectomy Breast Surgeryenrolling by invitationn=120
  • phase1Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participantscompletedn=13
  • phase1Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participantsactive not recruitingn=18
  • phase3Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgerynot yet recruitingn=100
  • phase3Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathyrecruitingn=734
  • phase4Evaluation of Pain Treatment After Total Knee Arthroplastyrecruitingn=60

News(10)

  • Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
    Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.
    biospace · 2d ago
  • Vertex, ahead of FDA decision, calms fears surrounding kidney drug
    On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
    biopharma_dive · 16d ago
  • Drug prices climb past $250K as US patients balk at the pharmacy
    Just one-third of patients prescribed new medicines filled them within 30 days, with a new report from the Institute for Clinical and Economic Review and West Health suggesting that cost is the pro…
    biospace · 29d ago
  • Most new drugs are still too costly at launch, ICER says
    A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.
    biopharma_dive · 1mo ago
  • Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in mice
    While psychedelic drugs may be capturing all the attention when it comes to finding fresh ways to treat neuropathic pain, research with mice has suggested a peptide approach may also be effective.
    fiercebiotech · 1mo ago
  • How J&J paved the way for Compass’ coming psychedelic drug launch
    In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Sprav…
    biopharma_dive · 1mo ago
  • Werewolf and Ambros to tie the knot in $150M rare disease deal
    The merger, which would create a new company bearing Ambros’ name, will help support development of Ambros' non-opioid painkiller for patients with debilitating limb injuries.
    biospace · 3mo ago
  • Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
    If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…
    biospace · 3mo ago
  • Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
    Antibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.
    fiercebiotech · 3mo ago
  • BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
    BlossomHill Therapeutics will use its $150 million IPO proceeds to power the Phase 1/2 development of a non-small cell lung cancer drug, while Latigo Therapeutics will bring in more than $345 milli…
    biospace · 3mo ago
view all news mentions →
brand
JOURNAVX
generic
SUZETRIGINE
MOA
12.1 Mechanism of Action Suzetrigine is a selective blocker of the Na V 1.8 voltage-gated sodium channel, compared to other known voltage-gated sodium channels (Na V 1.1 through 1.9). Na V 1.8 is expressed in peripheral sensory neurons including dorsal root ganglion neurons, where its role is to transmit pain signals (action potentials). By selectively inhibiting Na V 1.8 channels, suzetrigine inhibits transmission of pain signals to the spinal cord and brain. M6-SUZ, a major active metabolite, is a less potent inhibitor of Na V 1.8 than suzetrigine by 3.7-fold.
indication
1 INDICATIONS AND USAGE JOURNAVX is indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. JOURNAVX is a sodium channel blocker indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?